Formerly dba Diassess Inc, Lucira Health Inc is organized around tackling how infectious diseases can be prevented, diagnosed, and monitored by producing the next generation of rapid DNA testing implemented on smartphones. Effectively, the firm has developed tools that serve to transform smartphones into easy-to-use instruments allowing patients to test their own blood for changes in health quickly and often. The company's technology also has applications in forensics, the chemical industry, and agriculture. In 2018, Lucira Health (Diassess) had been awarded a 5 year, multi million dollar contract by Biomedical Advanced Research and Development Authority - BARDA - to provide professional-use, in-clinic flu diagnostic test and sustains development of the in-home, consumer-focused flu diagnostic test, the latter including the creation of a unique smartphone-based app connecting consumers to treatment options. The funding allowed the firm to take both tests through clinical trials and submit to the U.S. Food and Drug Administration (FDA) for clearance. Diassess flu diagnostic technologies gave physicians and consumers an accurate diagnosis within 20 minutes. Beginning with a nasal swab, the sample is inserted into a disposable DNA test. The battery-powered device quickly analyzes the sample and a visual readout indicates either influenza A, B or negative diagnosis. The in-home version uses a smartphone app to directly connect the consumer to treatment options. Clearly, the more recent claim to fame - Nov 2020 - is that the firm has become the first to received FDA approval for a self-administered at-home test for Corvid-19.